Menu Search
Equities

Hbm Holdings Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2142:HKG.HS

Hbm Holdings Ltd

Actions
  • Price (HKD)11.50
  • Today's Change-0.29 / -2.46%
  • Shares traded1.28m
  • 1 Year change+187.50%
  • Beta2.1451
Data delayed at least 15 minutes, as of Feb 13 2026 07:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.

  • Revenue in HKD (TTM)904.42m
  • Net income in HKD571.13m
  • Incorporated2016
  • Employees210.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.